SCM
AXSM icon

Superstring Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Superstring Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2M Buy
53,916
+42,699
+381% +$9.26M 8.33% 2
2026
Q1 		$1.9M Sell
11,217
-26,216
-70% -$4.53M 1.35% 24
2025
Q4 		$6.84M Buy
+37,433
New +$5.23M 3.66% 8
2025
Q1 		– Sell
-4,268
Closed -$361K – 35
2024
Q4 		$361K Buy
+4,268
New +$392K 0.31% 35
2024
Q2 		– Sell
-36,607
Closed -$2.92M – 44
2024
Q1 		$2.92M Buy
36,607
+20,428
+126% +$1.71M 1.93% 17
2023
Q4 		$1.29M Buy
+16,179
New +$1.08M 0.92% 23

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Superstring Capital Management's AXSM Position: Q2 2026 in Review

Superstring Capital Management increased its Axsome Therapeutics (AXSM) stake by 381% in Q2 2026, buying an estimated $9.26M and bringing the position to 53,916 shares worth $13.2M. The position accounts for 8.33% of the portfolio, ranked #2.

Superstring Capital Management first reported a position in AXSM in Q4 2023 and has held it in 6 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Superstring Capital Management held 53,916 shares of Axsome Therapeutics worth $13.2M as of Q2 2026.
  • Superstring Capital Management bought 42,699 Axsome Therapeutics shares in Q2 2026, an estimated $9.26M.
  • Axsome Therapeutics made up 8.33% of Superstring Capital Management's portfolio in Q2 2026, its #2 holding.
  • Superstring Capital Management first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.